InsiderSignalSign in
← Insider buys

RPRX

Royalty Pharma plc · Healthcare

Insiders sold $79.7M of Royalty Pharma plc in the last 12 months and bought none

$0Bought, 12 mo
$79.7MSold, 12 mo
$32.9BMarket cap
Follow RPRX

RPRX over the last year

No insider buys filed in this year

RPRX after insider buys

3 months after each buy, from the first price a copier could get.

−6.5%Average
−7.5 ptsVs S&P 500
1 of 4Higher

4 buys since 2022 with 3 months of prices.

Congress

Members reported 2 trades in RPRX since 2023.

Every filing

121 insider filings since 2020, newest first

RPRXSell

Marshall Urist · EVP, Research & Investments

$236K−100.0%Oct 5
RPRXSell

Marshall Urist · EVP, Research & Investments

$239K−50.0%Sep 30
RPRXSell

Christopher Hite · EVP & Chairman, Partnering

$5.9M−27.0%Sep 24
RPRXSell

Christopher Hite · EVP & Chairman, Partnering

$6.0M−21.3%Aug 19
RPRXSell

Terrance P. Coyne · EVP and CFO

$646K−100.0%Aug 17
RPRXSell

Marshall Urist · EVP, Research & Investments

$508K−100.0%Jul 2
RPRXSell

Christopher Hite · EVP & Chairman, Partnering

$7.3M−76.5%Jul 2
RPRXSell

Marshall Urist · EVP, Research & Investments

$502K−50.0%Jun 25
RPRXSell

Christopher Hite · EVP & Chairman, Partnering

$8.2M−21.1%Jun 25
RPRXSell

Terrance P. Coyne · EVP and CFO

$3.5M−100.0%May 28
RPRXSell

Marshall Urist · EVP, Research, Investments

$722K−27.0%May 21
RPRXSell

Marshall Urist · EVP, Research, Investments

$726K−21.0%May 15
RPRXSell

Gregory Norden · Director

$161K−2.0%May 15
RPRXSell

Terrance P. Coyne · EVP and CFO

$1.7M−28.0%Apr 30
RPRXSell

Terrance P. Coyne · EVP and CFO

$1.7M−22.0%Apr 2
RPRXSell

Terrance P. Coyne · EVP and CFO

$1.6M−18.0%Mar 25
RPRXSell

Terrance P. Coyne · EVP and CFO

$1.6M−15.0%Mar 4
RPRXSell

Terrance P. Coyne · EVP and CFO

$1.6M−13.0%Feb 25
RPRXSell

Marshall Urist · EVP, Research, Investments

$822K−43.0%Feb 2
RPRXSell

Marshall Urist · EVP, Research, Investments

$805K−30.0%Jan 26
RPRXSell

Terrance P. Coyne · EVP and CFO

$2.7M−13.0%Jan 23
RPRXSell

Marshall Urist · EVP, Research, Investments

$790K−23.0%Jan 20
RPRXSell

Marshall Urist · EVP, Research, Investments

$816K−19.0%Jan 13
RPRXSell

Terrance P. Coyne · EVP and CFO

$2.7M−11.0%Jan 6
RPRXSell

Marshall Urist · EVP, Research, Investments

$770K−16.0%Jan 6
RPRXSell

Marshall Urist · EVP, Research, Investments

$786K−14.0%Dec 29
RPRXSell

Marshall Urist · EVP, Research, Investments

$768K−12.0%Dec 22
RPRXSell

George W. Lloyd · EVP, Investments, CLO

$4.2M−12.0%Dec 19
RPRXSell

Marshall Urist · EVP, Research, Investments

$766K−11.0%Dec 17
RPRXSell

Terrance P. Coyne · EVP and CFO

$2.7M−10.0%Dec 17
RPRXSell

Marshall Urist · EVP, Research, Investments

$1.6M−18.0%Dec 9
RPRXSell

George W. Lloyd · EVP, Investments, CLO

$4.4M−11.0%Dec 5
RPRXSell

Terrance P. Coyne · EVP and CFO

$2.8M−9.0%Dec 3
RPRXSell

Marshall Urist · EVP, Research, Investments

$1.7M−15.0%Dec 3
RPRXSell

Terrance P. Coyne · EVP and CFO

$2.7M−8.0%Nov 26
RPRXSell

George W. Lloyd · EVP, Investments, CLO

$5.2M−12.0%Nov 21
RPRXSell

Rory B Riggs · Director

$13.2M−80.0%Jan 4
RPRXSell

Avara Management Ltd · 10% owner

$1.8MJan 3
RPRXSell

Avara Management Ltd · 10% owner

$7.1M−1.0%Dec 29
RPRXSell

Avara Management Ltd · 10% owner

$286KDec 19
RPRXSell

Avara Management Ltd · 10% owner

$19.5M−2.0%Dec 15
RPRXSell

Terrance P. Coyne · EVP and CFO

$2.3M−8.0%Aug 11
RPRXSell

Terrance P. Coyne · EVP and CFO

$2.3M−8.0%Jul 14
RPRXBuy

Pablo G. Legorreta · CEO, Chair and 10% owner

$3.8M+4.0%Jun 28
RPRXBuy

Pablo G. Legorreta · CEO, Chair and 10% owner

$3.0M+3.0%Jun 13
RPRXSell

George W. Lloyd · EVP, Investments, CLO

$6.5M−17.0%Jun 6
RPRXSell

Rory B Riggs · Director

$57.4M−94.0%May 22
RPRXBuy

Pablo G. Legorreta · CEO, Chair and 10% owner

$7.7M+7.0%May 17
RPRXSell

Rory B Riggs · Director

$5.1M−8.0%Mar 30
RPRXSell

George W. Lloyd · EVP, Investments, CLO

$4.2M−9.0%Mar 30
Older filings
About Royalty Pharma plc

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 20 development-stage product candidates that address various therapeutic areas, such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. The company has research and development funding collaboration to advance the development of JNJ-4804, an investigational medicine for autoimmune diseases. The company was founded in 1996 and is based in New York, New York.

Filings come from SEC EDGAR and prices from daily closes. Not investment advice.